Increased risk of chronic fatigue syndrome following psoriasis: a nationwide population-based cohort study

Table 3 Incidence density rates and hazard ratios of chronic fatigue syndrome according to psoriasis status stratified by sex, age, and comorbidity

Variables	Non-psoriasis group			Psoriasis group			Compared to non-psoriasis group
	Non-psoriasis group			Psoriasis group			HR (95% CI)
	Event no.	Person-year	IR	Event no.	Person-year	IR	Crude	Adjusted^a
Sex
Women	71	25,959	2.74	20	6551	3.05	1.11 (0.68–1.83)	1.07 (0.65–1.77)
Men	55	29,488	1.87	30	7407	4.05	2.17 (1.39–3.39)***	2.05 (1.31–3.20)**
Age, years
20–39	48	25,231	1.90	14	6368	2.20	1.16 (0.64–2.10)	1.16 (0.64–2.11)
40–59	44	19,182	2.29	16	4792	3.34	1.46 (0.82–2.58)	1.26 (0.71–2.45)
≥ 60	34	11,034	3.08	20	2797	7.15	2.32 (1.34–4.04)**	2.32 (1.33–4.06)**
Comorbidity status^b
No	63	41,393	1.52	23	9278	2.48	1.63 (1.01–2.63)*	1.66 (1.03–2.67)*
Yes	63	14,054	4.48	27	4680	5.77	1.29 (0.82–2.02)	1.29 (0.82–2.03)

IR incidence density rate per 1000 person-years, HR hazard ratio, CI confidence interval
* P < 0.05, ** P < 0.01, *** P < 0.001
^aModel mutually adjusted for sex, age, diabetes, depression, anxiety, sleep disorder, and renal disease
^bPatients exhibiting diabetes, depression, anxiety, sleep disorder, or renal disease were classified as the comorbidity group

ISSN: 1479-5876